BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22065993)

  • 1. CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.
    Feng Z; Guo W; Zhang C; Xu Q; Zhang P; Sun J; Zhu H; Wang Z; Li J; Wang L; Wang B; Ren G; Ji T; Tu W; Yang X; Qiu W; Mao L; Zhang Z; Chen W
    PLoS One; 2011; 6(10):e26399. PubMed ID: 22065993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.
    Chiu TJ; Chen CH; Chien CY; Li SH; Tsai HT; Chen YJ
    J Transl Med; 2011 Mar; 9():31. PubMed ID: 21426588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
    Ock CY; Keam B; Kim TM; Han DH; Won TB; Lee SH; Hah JH; Kwon TK; Kim DW; Kim DY; Rhee CS; Wu HG; Sung MW; Heo DS
    Korean J Intern Med; 2016 May; 31(3):570-8. PubMed ID: 26976150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report.
    Akervall J; Brun E; Dictor M; Wennerberg J
    Acta Oncol; 2001; 40(4):505-11. PubMed ID: 11504311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
    Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NM23-H1 expression of head and neck squamous cell carcinoma in association with the response to cisplatin treatment.
    Wang YF; Chang CJ; Chiu JH; Lin CP; Li WY; Chang SY; Chu PY; Tai SK; Chen YJ
    Oncotarget; 2014 Sep; 5(17):7392-405. PubMed ID: 25277180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma.
    Fan Y; Jiang Y; Zhou X; Chen Q; Huang Z; Xu Y; Gong L; Yu H; Yang H; Liu J; Lei T; Zhao Q; Mao W
    Oncotarget; 2016 Aug; 7(31):50624-50634. PubMed ID: 27244882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
    Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
    Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
    Kuhnt T; Mueller AC; Pelz T; Haensgen G; Bloching M; Koesling S; Schubert J; Dunst J
    J Cancer Res Clin Oncol; 2005 Nov; 131(11):758-64. PubMed ID: 16088405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
    Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
    Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas.
    Hanken H; Gröbe A; Cachovan G; Smeets R; Simon R; Sauter G; Heiland M; Blessmann M
    Clin Oral Investig; 2014 Jan; 18(1):269-76. PubMed ID: 23494454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma.
    Ishiguro R; Fujii M; Yamashita T; Tashiro M; Tomita T; Ogawa K; Kameyama K
    Anticancer Res; 2003; 23(6D):5213-20. PubMed ID: 14981992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
    Su YY; Chien CY; Luo SD; Huang TL; Lin WC; Fang FM; Chiu TJ; Chen YH; Lai CC; Hsu CM; Li SH
    World J Surg Oncol; 2016 Mar; 14():86. PubMed ID: 27001663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of XIAP and CIAP1 Play Synergistic Effect on Patient's Prognosis in Head and Neck Cancer.
    Yang XH; Liu L; Hu YJ; Zhang P; Hu QG
    Pathol Oncol Res; 2019 Jul; 25(3):1111-1116. PubMed ID: 30421089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of qualitative regression grading as a prognostic factor for survival after preoperative radiochemotherapy in patients with advanced head and neck cancer].
    Hermann RM; Krech R; Hartlapp J; Esser E; Christoph B; Müller MK; Wagner W
    Strahlenther Onkol; 2001 Jun; 177(6):277-82. PubMed ID: 11446315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma.
    Park MJ; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
    Eur J Cancer; 2018 Mar; 92():69-76. PubMed ID: 29428866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of squamous cell carcinoma of external auditory canal: A tertiary cancer centre experience.
    Gandhi AK; Roy S; Biswas A; Raza MW; Saxena T; Bhasker S; Sharma A; Thakar A; Mohanti BK
    Auris Nasus Larynx; 2016 Feb; 43(1):45-9. PubMed ID: 26165629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.